Advertisement

Topics

Marina Biotech Enters Agreement with Autotelic Bio

03:12 EST 17 Jan 2018 | Topix

Marina Biotech has entered into a binding license agreement with Autotelic Bio for the exclusive development and marketing outside of the United States and Canada of Marina's IT-103 clinical program. Under the agreement, Autotelic Bio will obtain a perpetual license to have the right and responsibility to begin clinical development of IT-103 for marketing approval in South Korea and territories outside of United States and Canada.

Original Article: Marina Biotech Enters Agreement with Autotelic Bio

NEXT ARTICLE

More From BioPortfolio on "Marina Biotech Enters Agreement with Autotelic Bio"

Advertisement
Quick Search
Advertisement
Advertisement